Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ZS Pharma

- PMLiVE

Roche and AstraZeneca to share early trial data

Unique big pharma collaboration aims to increase their R&D efficiency

- PMLiVE

Sanofi and AstraZeneca form cancer research alliances with non-profits

Will work respectively with Curie Institute in France and Cancer Research UK

- PMLiVE

Celgene wins expanded EU approval for cancer drug Revlimid

Approved for use in patients with rare blood disorder

- PMLiVE

AstraZeneca picks location for global HQ and research base

Decides on the Cambridge Biomedical Campus in UK

- PMLiVE

AstraZeneca and NGM form diabetes/ obesity partnership

Will use MedImmune arm to develop treatments that target gastrointestinal hormones

- PMLiVE

AstraZeneca boosts R&D prospects with Pearl acquisition

Deal to acquire respiratory firm could be worth up to $1.15bn

- PMLiVE

FDA gives priority review status to BMS/ AZ’s metreleptin

Former obesity prospect has potential in the rare disease lipodystrophy

- PMLiVE

AstraZeneca drops arthritis candidate fostamatinib

Hands rights back to Rigel after late-stage trial disappointment

- PMLiVE

EMA backs Pomalidomide Celgene in multiple myeloma

Further positive CHMP opinions for new medicines form Aegerion, Teva and more

- PMLiVE

GSK/ Valeant’s Trobalt set for EU restrictions

Eye concerns prompt CHMP to recommend last-line use for the epilepsy drug

EU flag

EU Parliament panel backs updated clinical trials regulations

But pharma industry concerned about measures to increase transparency

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links